Free Trial

Adagene (ADAG) Competitors

Adagene logo
$1.91 -0.04 (-2.05%)
Closing price 10/13/2025 03:59 PM Eastern
Extended Trading
$1.95 +0.04 (+2.09%)
As of 10/13/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADAG vs. REPL, DMAC, BNTC, LXEO, IMAB, ALT, DBVT, EDIT, ALTS, and ANNX

Should you be buying Adagene stock or one of its competitors? The main competitors of Adagene include Replimune Group (REPL), DiaMedica Therapeutics (DMAC), Benitec Biopharma (BNTC), Lexeo Therapeutics (LXEO), I-Mab (IMAB), Altimmune (ALT), DBV Technologies (DBVT), Editas Medicine (EDIT), ALT5 Sigma (ALTS), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry.

Adagene vs. Its Competitors

Replimune Group (NASDAQ:REPL) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

In the previous week, Adagene had 1 more articles in the media than Replimune Group. MarketBeat recorded 3 mentions for Adagene and 2 mentions for Replimune Group. Replimune Group's average media sentiment score of 0.95 beat Adagene's score of 0.83 indicating that Replimune Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Replimune Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Adagene
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 5.2% of Replimune Group shares are owned by company insiders. Comparatively, 21.2% of Adagene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Replimune Group has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Adagene has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

Adagene has higher revenue and earnings than Replimune Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Replimune GroupN/AN/A-$247.30M-$3.24-1.41
Adagene$100K900.18-$33.42MN/AN/A

Replimune Group presently has a consensus price target of $6.50, indicating a potential upside of 42.54%. Adagene has a consensus price target of $7.00, indicating a potential upside of 266.49%. Given Adagene's stronger consensus rating and higher probable upside, analysts clearly believe Adagene is more favorable than Replimune Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Replimune Group
3 Sell rating(s)
6 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
1.91
Adagene
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60

Adagene's return on equity of 0.00% beat Replimune Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Replimune GroupN/A -69.34% -52.81%
Adagene N/A N/A N/A

Summary

Adagene beats Replimune Group on 10 of the 12 factors compared between the two stocks.

Get Adagene News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADAG vs. The Competition

MetricAdageneMED IndustryMedical SectorNASDAQ Exchange
Market Cap$91.91M$3.36B$6.05B$10.30B
Dividend YieldN/A2.31%5.73%4.82%
P/E RatioN/A22.0885.3127.10
Price / Sales900.18478.69601.46133.24
Price / CashN/A44.9825.7730.18
Price / Book1.6810.3812.676.69
Net Income-$33.42M-$52.47M$3.32B$276.55M
7 Day Performance-4.02%0.18%-0.06%-0.40%
1 Month Performance-14.73%13.95%8.73%6.53%
1 Year Performance-13.57%20.83%78.85%41.04%

Adagene Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADAG
Adagene
2.4836 of 5 stars
$1.91
-2.1%
$7.00
+266.5%
-9.9%$91.91M$100K0.00260
REPL
Replimune Group
4.6768 of 5 stars
$4.68
-1.1%
$6.50
+38.9%
-60.3%$369.21MN/A-1.44210Positive News
DMAC
DiaMedica Therapeutics
1.9108 of 5 stars
$6.93
-2.0%
$12.33
+78.0%
+66.1%$365.44MN/A-10.0420
BNTC
Benitec Biopharma
1.9683 of 5 stars
$13.66
-1.3%
$24.80
+81.6%
+38.1%$363.30MN/A-9.2920
LXEO
Lexeo Therapeutics
2.7526 of 5 stars
$6.47
-2.3%
$15.33
+137.0%
+0.1%$357.49MN/A-1.9858
IMAB
I-Mab
2.73 of 5 stars
$4.35
+0.7%
$7.33
+68.6%
+355.9%$355.22MN/A0.00380Analyst Upgrade
Gap Up
ALT
Altimmune
2.9713 of 5 stars
$4.01
+2.6%
$17.40
+333.9%
-36.5%$353.91M$20K-3.4050Analyst Forecast
DBVT
DBV Technologies
1.3241 of 5 stars
$13.29
+3.0%
$14.75
+11.0%
+373.5%$353.40MN/A-2.7980High Trading Volume
EDIT
Editas Medicine
4.2632 of 5 stars
$3.80
-3.1%
$5.10
+34.2%
+11.6%$352.49M$38.90M-1.33230
ALTS
ALT5 Sigma
0.4935 of 5 stars
$2.95
+2.8%
N/A+34.3%$351.89M$12.53M0.00170Positive News
Gap Down
ANNX
Annexon
2.4709 of 5 stars
$3.18
-0.3%
$12.50
+293.1%
-59.2%$349.44MN/A-2.4760Positive News

Related Companies and Tools


This page (NASDAQ:ADAG) was last updated on 10/14/2025 by MarketBeat.com Staff
From Our Partners